According to the research report titled ‘United States Vaccines Market 2015 - 2025: Top 21 Vaccines Analysis, Deal Trends, Players and Forecasts’, United States vaccines market is projected to observe considerable growth over 2021-2027, reaching a valuation of USD 21 billion by the end of the forecast period.
 

Increase in technological advancements, surging cases of infectious diseases, emergence of new vaccines, and shifting government focus on immunization programs are propelling United States vaccines market growth. Moreover, increasing research & development activities, and rising disease cognizance are adding to the industry development.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/1335756/
 

In the coming years, rising healthcare spending is likely to present new opportunities for market development. Besides, support from major authorities such as World Health Organization (WHO) is anticipated to expand the possibility for vaccine production and supply in the economy.
 

Experts cite that hefty cost of vaccine production, extended durations necessary for its development, and emerging variants are anticipated to hinder market growth.
 

The top 21 vaccines covered in the United States vaccines market research report are Rotarix, Rotateq, Shingrix, Havrix/Twinrix/Engerix-B, Boostrix, Trumenba, Proquad,Varivax, Gardasil/Gardasil 9, Prevnar/Prevnar 13, Fluzone, Menactra, Pneumovax, FluLaval/Fluarix, MMR II, Adacel, Bexsero, Menveo, Pentacel, Recombivax HB, and Pediarix/Infanrix.
 

The report thoroughly analyzes the market share captured and revenue generated by each vaccine with seven-year forecasts. It elaborates on the pricing trends, clinical development by major companies, and various vaccines available in the vertical. It also assesses the distribution channel, and offers a detailed account of the distribution and demand in the country.
 

Major players operating in the market are GlaxoSmithKline (GSK) plc, Sanofi Pasteur, Merck KGaA, and Pfizer Inc. The top companies are assessed based on a number of factors, including their commercial outlook, promising vaccines in clinical development, and recent developments.
 

To combat the coronavirus, the corporations are aggressively working on improving their production capacity and investing in vaccine R&D. In addition, the document entails strategic developments undertaken by the key industry players to sustain their market share and boost income flow.